Vivalis announced today that it signed another research license for use of its novel EB66 duck stem cell line with Kyoto Biken, one of Japan's largest animal vaccine manufacturers. We've worked closely with Vivalis to develop animal-component free and chemically-defined media for the EB66 platform used by their licensees. Vivalis has many other research licensees and 14 commerical license holders, including some of the largest vaccine manufacturers in the world, for specific diseases - particularly in the influenza and HIV arena.
A complete list of commercial license holders can be found in the Corporate portion of the Vivalis website. Several of these companies are using the EB66 and medium platform in clincial studies and have progressed to phase II.
In addition to vaccine work, Vivalis continues to explore applications for the EBx cell lines in recombinant protein expression for therapeutics.
Posted by Bruce Lehr Feb 17, 2010.